Skip to content
Screener

EyePoint, Inc. EYPT Total Liabilities & Equity

Total Liabilities & Equity at other companies

Merck & Co. logo
Merck & Co.MRK
$129.8B+10.4%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$732.53M+80.5%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$306.01M+2.7%
Regenxbio logo
RegenxbioRGNX
$386.62M-33.5%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$512.91M-0.5%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemJune 30, 2026December 31, 2025
Stockholders' equity:
Preferred stock, $.001 par value, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $.001 par value, 300,000,000 shares authorized at June 30, 2026 and December 31, 2025; 84,981,843 and 82,826,416 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively8583
Additional paid-in capital1,449,8131,410,047
Accumulated deficit(1,284,280)(1,104,978)
Accumulated other comprehensive income (loss)793961
Total stockholders' equity166,411306,113
Total liabilities and stockholders' equity$228,191$363,996

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s total liabilities & equity?
EyePoint, Inc. (EYPT) reported total liabilities & equity of $228.19M in Q2 2026.
How has EyePoint, Inc.'s total liabilities & equity changed year-over-year?
EyePoint, Inc.'s total liabilities & equity decreased by 24.2% year-over-year, from $301.15M to $228.19M.
What is the long-term trend for EyePoint, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), EyePoint, Inc.'s total liabilities & equity has grown at a 31.7% compound annual growth rate (CAGR), from $91.72M to $364M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about EyePoint, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude